Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iloperidone
Drug ID BADD_D01134
Description Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Indications and Usage Treatment of acute schizophrenia.
Marketing Status approved
ATC Code N05AX14
DrugBank ID DB04946
KEGG ID D02666
MeSH ID C081732
PubChem ID 71360
TTD Drug ID D0M8VE
NDC Product Code 46016-1332; 43068-102; 51672-4178; 51672-4213; 43068-101; 43068-108; 51672-4180; 50379-0006; 63285-755; 63285-756; 66499-0067; 51672-4182; 0378-0632; 0378-0633; 43068-104; 43068-106; 43068-110; 66499-0042; 51672-4183; 0378-0631; 66022-0115; 43068-901; 51672-4181; 0378-0636; 43068-112; 43068-902; 0378-0634; 0378-0635; 43068-903; 0378-0630; 43068-113; 51672-4179; 51672-4184
UNII VPO7KJ050N
Synonyms iloperidone | Fanapt | HP 873 | HP-873 | Zomaril
Chemical Information
Molecular Formula C24H27FN2O4
CAS Registry Number 133454-47-4
SMILES CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle spasms15.05.03.004--
Myalgia15.05.02.0010.000444%
Nasal congestion22.04.04.0010.000889%
Nasal dryness22.04.03.002--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001--Not Available
Neutrophil count increased13.01.06.011--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Obsessive-compulsive disorder19.06.05.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.0110.000418%
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000418%Not Available
Palpitations02.11.04.012--
Panic attack19.06.04.001--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Paranoia19.05.01.005--Not Available
Parkinsonism17.01.05.003--Not Available
Pollakiuria20.02.02.007--
Polydipsia psychogenic19.24.01.004; 14.05.02.002--Not Available
Priapism24.04.12.007; 21.03.01.0050.000483%Not Available
Prostatitis21.09.01.001--Not Available
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pulmonary embolism22.06.02.001; 24.01.06.0010.000131%Not Available
Rash23.03.13.001--Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000131%Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retrograde ejaculation21.03.01.0060.001555%Not Available
Rhinorrhoea22.12.03.021--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene